Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 11:12:828112.
doi: 10.3389/fonc.2022.828112. eCollection 2022.

Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis

Affiliations
Review

Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis

Carla Enrica Gallenga et al. Front Oncol. .

Abstract

Uveal melanoma (UM) is the most frequently found primary intraocular tumor, although it accounts for only 5% of all melanomas. Despite novel systemic therapies, patient survival has remained poor. Indeed, almost half of UM patients develop metastases from micro-metastases which were undetectable at diagnosis. Genetic analysis is crucial for metastatic risk prediction, as well as for patient management and follow-up. Several prognostic parameters have been explored, including tumor location, basal dimension and thickness, histopathologic cell type, vascular mimicry patterns, and infiltrating lymphocytes. Herein, the Authors review the available literature concerning cytogenetic prognostic markers and biochemical pathways correlated to UM metastasis development.

Keywords: genetic analyses; metastasis; molecular mechanism; prognostic markers; uveal melanoma (UM).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Graphical Abstract
Graphical Abstract
Red boxes represent high metastatic risk factors; orange box represents intermediate metastatic risk factor (late onset metastasis); green boxes represent low metastatic risk factors.
Figure 1
Figure 1
Haematoxylin-eosin histopathological analysis of uveal melanoma. (With permission of Prof. Giovanni Lanza, Institute of Pathological Anatomy, University of Ferrara).
Figure 2
Figure 2
Malignant choroidal melanoma showing masses of neoplastic epithelioid cells invading a tumor vessel lumen. (Reproduced with permission from Prof. Gallenga P.E., Rass. Ital. Ottal.; published by Clinica oculistica dell’Università di Torino, 1961).

References

    1. Singh AD, Turell ME, Topham AK. Uveal Melanoma: Trends in Incidence, Treatment, and Survival. Ophthalmology (2011) 118:1881–5. doi: 10.1016/j.ophtha.2011.01.040 - DOI - PubMed
    1. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. . Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma. Arch Ophthalmol (2005) 123(12):1639–43. doi: 10.1001/archopht.123.12.1639 - DOI - PubMed
    1. Kujala E, Mäkitie T, Kivelä T. Very Long-Term Prognosis of Patients With Malignant Uveal Melanoma. Investig Ophthalmol Vis Sci (2003) 44:4651–9. doi: 10.1167/iovs.03-0538 - DOI - PubMed
    1. Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivela T. Metastatic Uveal Melanoma: The Final Frontier. Retin Eye Res (2022) 101041. doi: 10.1016/j.preteyeres - DOI - PubMed
    1. Seddon JM, Albert DM, Robinson N, Lavin PT. A Prognostic Factor Study Of Disease-Free Interval and Survival Following Enucleation for Uveal Melanoma. Arch Ophthalmol (1983) 101:1894–9. doi: 10.1001/archopht.1983.01040020896012 - DOI - PubMed

LinkOut - more resources